FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to methods for increasing therapeutic efficacy of fexapotide triflutate in patients with lower urinary tract symptoms. Method of increasing therapeutic efficacy of fexapotide triflutate (FT) by improving at least one of the average change in peak flow rate (Qmax) from baseline and/or inhibition of deterioration/obstruction of urine flow when determined by failure to provide urine volume >125 ml, in patients with lower urinary tract symptoms (LUTS), wherein the method improves at least one of the average change in Qmax compared to the baseline and/or deterioration/obstruction of the urine flow when determined by the inability to provide a urine volume >125 ml, in an amount exceeding the corresponding improvement in patients who received the same total dose of FT or double the total dose of FT in one administration, where the method involves: (a) identification and selection of patients with obstructive LUTS; (b) initial administration of a first composition containing 2.5 mg of FT, to a patient in need thereof, and selected in the above a); and c) subsequent administration of a second composition containing 2.5 mg of FT to the patient at least more than one year after the first administration. Method of increasing therapeutic efficacy of FT in improving at least nocturia in patients with LUTS, wherein the method improves at least nocturia to a greater extent than the improvement of nocturia in patients who received the same total dose of FT in a single administration, where the method involves: (a) identifying and selecting patients having irritation symptoms as LUTS; (b) administering a first composition containing 2.5 mg of FT to a patient selected in a) above; and (c) administering a second composition containing 2.5 mg of FT to a patient at least more than one year after administration of the first composition. Method of increasing therapeutic efficacy of FT in treating obstructive symptoms in patients with LUTS, wherein the method improves at least one obstructive symptom as a LUTS in an amount exceeding the corresponding improvement in the patients receiving the same total dose of FT or a double total dose of FT in a single administration, wherein the method comprises: (a) identifying and selecting patients having obstructive symptoms as LUTS; (b) administering a first composition containing 2.5 mg of FT to a patient identified and selected in a) above; and (c) administering a second composition containing 2.5 mg of FT to a patient at least one year after administration of the first composition.
EFFECT: said group of inventions enables improving therapeutic efficacy of fexapotide triflutate and quality of life in patients with LUTS.
10 cl, 6 tbl, 3 ex
